Galtier J, Basile G, Bouabdallah K. Response to comment on: "Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience". Haematologica; https://doi.org/10.3324/haematol.2026.301477 [Early view].